The Acute Lymphoblastic Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Lymphoblastic Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Lymphoblastic Lymphoma. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Lymphoblastic Lymphoma and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Acute Lymphoblastic Lymphoma by 17 companies/universities/institutes. The top development phase for Acute Lymphoblastic Lymphoma is phase i with six drugs in that stage. The Acute Lymphoblastic Lymphoma pipeline has nine drugs in development by companies and nine by universities/ institutes. Some of the companies in the Acute Lymphoblastic Lymphoma pipeline products market are: PersonGen BioTherapeutics (Suzhou), King Abdullah International Medical Research Center and Children’s Hospitals and Clinics of Minnesota.

The key targets in the Acute Lymphoblastic Lymphoma pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7), and Cells Expressing T Cell Surface Glycoprotein CD1a (T Cell Surface Antigen T6/Leu 6 or hTa1 Thymocyte Antigen or CD1A).

The key mechanisms of action in the Acute Lymphoblastic Lymphoma pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with eight drugs in Phase II. The Acute Lymphoblastic Lymphoma pipeline products include four routes of administration with the top ROA being Intravenous and three key molecule types in the Acute Lymphoblastic Lymphoma pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.

Acute Lymphoblastic Lymphoma overview

Acute lymphoblastic lymphoma (ALL) is a heterogeneous hematologic malignancy involving proliferation of lymphoid progenitor cells (of B cell or T cell lineage) that invades bone marrow, peripheral blood, and extramedullary locations. ALL is a disease with ≥ 20% of lymphoblasts (atypical lymphoid or undifferentiated cells) in bone marrow lymphoblasts or peripheral blood.

For a complete picture of Acute Lymphoblastic Lymphoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.